In parallel, a phase I–II clinical trial of mTOR inhibitors on a panel of pediatric tumors revealed a plausible therapeutic benefit in a few advanced osteosarcoma cases23, 24, 25. The gene discussed is MTOR; the disease is osteosarcoma.